NORP – Talk Bio

FDA Lifts Clinical Hold on Intellia’s MAGNITUDE-2 Phase 3 Trial for Nex-Z in ATTRv-PN

2 days ago talkbio0Tagged ATTRv-PN, Clustered Regularly Interspaced Short Palindromic Repeats, Gene Modification, Intellia, MAGNITUDE-2, nex-z, Study on Hold, United States Food and Drug Administration

FDA; Intellia Therapeutics; clinical hold; MAGNITUDE-2; nex-z; ATTRv-PN; gene editing; CRISPR

FDA Places Clinical Holds on Regenxbio’s RGX-111 and RGX-121 Gene Therapy Trials After Brain Tumor in Patient

2 days ago talkbio0Tagged AAV Vector, Brain Neoplasms, Clinical, gene therapy, Mucopolysaccharidosis I, Mucopolysaccharidosis II, Regenxbio, RGX-111, RGX-121, United States Food and Drug Administration

FDA clinical hold; Regenxbio; RGX-111; RGX-121; brain tumor; gene therapy; MPS I; MPS II; AAV vector

J&J Brushes Off MFN Impact, Forecasts $100 Billion Revenue Milestone for 2026

1 week ago talkbio0Tagged Innovative Medicine, J&J, Johnson & Johnson, medtech, MFN, Projections and Predictions, Trump drug pricing

J&J; Johnson & Johnson; MFN; Trump drug pricing; 2026 forecast; $100 billion; MedTech; Innovative Medicine

JPM26: BMS Highlights Early-Stage Bets and Pipeline Progress Amid Late-Stage Pharma Focus

2 weeks ago talkbio0Tagged Admilparant, Burning Mouth Syndrome, Camzyos, Cobenfy, Early-stage, JPM26, milvexian, pipeline, pumitamig

BMS; JPM26; early-stage bets; pipeline; Cobenfy; Milvexian; Admilparant; Pumitamig; Camzyos

Lilly Bulks Up Inflammatory Pipeline With $1.2B Ventyx Buy, InduPro Cancer Pact

3 weeks ago talkbio0Tagged Autoimmune, cardiometabolic, Eli, Eli Lilly, Immunotherapy for cancer, InduPro * *, Inflammatory disorder, M&A, Neoplasms, Neuroinflammation, NLRP3 inhibitors, Obesity, Ventyx Biosciences, VTX3232, VTX958

Eli Lilly; Lilly; Ventyx Biosciences; InduPro; inflammatory diseases; oncology; NLRP3 inhibitors; tamuzimod; VTX2735; VTX3232; VTX958; autoimmune; obesity; cardiometabolic; neuroinflammation; M&A; biotech deal; cancer immunotherapy

Parabilis raises $305M to advance Helicon peptide cancer drugs against ‘undruggable’ targets

3 weeks ago talkbio0Tagged cancer drug development, Capital, Fibromatosis, Aggressive, fidelity, FOG-001, FogPharma, Helicon peptide platform, Janus Henderson, Malignant neoplasm of prostate, Parabilis Medicines, Rheumatoid Arthritis, Series F financing, targets, venture capital, zolucatetide

Parabilis Medicines; FogPharma; $305 million; Series F financing; undruggable targets; Helicon peptide platform; zolucatetide; FOG-001; desmoid tumors; prostate cancer; cancer drug development; venture capital; RA Capital; Fidelity; Janus Henderson

Parabilis raises $305M to advance Helicon peptide cancer drugs against ‘undruggable’ targets

3 weeks ago talkbio0Tagged cancer drug development, Capital, Fibromatosis, Aggressive, fidelity, FOG-001, FogPharma, Helicon peptide platform, Janus Henderson, Malignant neoplasm of prostate, Parabilis Medicines, Rheumatoid Arthritis, Series F financing, targets, venture capital, zolucatetide

Parabilis Medicines; FogPharma; $305 million; Series F financing; undruggable targets; Helicon peptide platform; zolucatetide; FOG-001; desmoid tumors; prostate cancer; cancer drug development; venture capital; RA Capital; Fidelity; Janus Henderson

Parabilis raises $305M to advance Helicon peptide cancer drugs against ‘undruggable’ targets

3 weeks ago talkbio0Tagged cancer drug development, Capital, Fibromatosis, Aggressive, fidelity, FOG-001, FogPharma, Helicon peptide platform, Janus Henderson, Malignant neoplasm of prostate, Parabilis Medicines, Rheumatoid Arthritis, Series F financing, targets, venture capital, zolucatetide

Parabilis Medicines; FogPharma; $305 million; Series F financing; undruggable targets; Helicon peptide platform; zolucatetide; FOG-001; desmoid tumors; prostate cancer; cancer drug development; venture capital; RA Capital; Fidelity; Janus Henderson

Parabilis raises $305M to advance Helicon peptide cancer drugs against ‘undruggable’ targets

3 weeks ago talkbio0Tagged cancer drug development, Capital, Fibromatosis, Aggressive, fidelity, FOG-001, FogPharma, Helicon peptide platform, Janus Henderson, Malignant neoplasm of prostate, Parabilis Medicines, Rheumatoid Arthritis, Series F financing, targets, venture capital, zolucatetide

Parabilis Medicines; FogPharma; $305 million; Series F financing; undruggable targets; Helicon peptide platform; zolucatetide; FOG-001; desmoid tumors; prostate cancer; cancer drug development; venture capital; RA Capital; Fidelity; Janus Henderson

Alumis’ TYK2 Inhibitor Envudeucitinib Succeeds in Phase 3 Psoriasis Trials, Plans FDA Filing

3 weeks ago talkbio0Tagged Alumis, Approved, envudeucitinib, Phase 3 trials, Psoriasis, Psoriasis Area and Severity Index Clinical Classification, TYK2 Inhibitor, United States Food and Drug Administration

Alumis; envudeucitinib; TYK2 inhibitor; psoriasis; Phase 3 trials; FDA approval; PASI 75